Determinants Of Immune Restoration Disease And Persistent Immune Dysfunction In HIV Patients Responding To ART
Funder
National Health and Medical Research Council
Funding Amount
$445,011.00
Summary
Many people throughout the world now receive antiretroviral treatment (ART) for HIV-AIDS. ART increases numbers of CD4 T-cells, but does not restore all functions the immune system. In addition, some patients experience serious exacerbations of pre-existing secondary infections when they respond to ART. We were the first to describe these Immune Restoration Diseases and will investigate the underlying mechanisms and the causes of persistent immune deficiency here.
Dissecting Mechanisms Of Generalised Immune Activation And Cellular Dysfunction In HIV Infection
Funder
National Health and Medical Research Council
Funding Amount
$422,576.00
Summary
How HIV infection compromises the host immune system is still not well understood. We will study how HIV surface proteins contribute to heightened immune activation during chronic infection. This generalised activation eventually leads to dysfunctional cellular immune responses and loss of partial control of infection. We will additionally investigate the extent and impact of the loss of functional immune responses in chronic HIV infection.
This program application seeks to draw on the skills of a world leading group of Australian researchers to bring novel HIV vaccine designs to clinical trials, improve vaccine design and create new opportunities for commercialisation. The Chief Investigators, Prof David Cooper, Prof Peter Doherty (Nobel Prize winner), A-Prof Stephen Kent and Prof Ian Ramshaw, have achieved major scientific developments including: innovative collaborative clinical trials, cutting edge research in T cell immunology ....This program application seeks to draw on the skills of a world leading group of Australian researchers to bring novel HIV vaccine designs to clinical trials, improve vaccine design and create new opportunities for commercialisation. The Chief Investigators, Prof David Cooper, Prof Peter Doherty (Nobel Prize winner), A-Prof Stephen Kent and Prof Ian Ramshaw, have achieved major scientific developments including: innovative collaborative clinical trials, cutting edge research in T cell immunology, the establishment of the only PC3-level nonhuman primate facility in the Southern hemisphere, T cell immunogenicity of the DNA-viral vector prime-boost vaccine regimens and ground-breaking research on cytokine co-expressing viral vector vaccines. The Principle Investigators also have a record of substantial achievement in relation to HIV and T cell biology as well as novel vaccination technologies. There is a strong history of successful collaboration among this group leading to the award of major NIH funding.Read moreRead less
Herpes Simplex Virus Type 2 Modulates The HIV-1 Infection Of Plasmacytoid And Myeloid Dendritic Cells.
Funder
National Health and Medical Research Council
Funding Amount
$76,637.00
Summary
The aim of my project is to find out why people with herpes simplex virus are more susceptible to HIV infection. Herpes simplex is a common sexually transmitted disease and causes genital ulcers in both men and women. Understanding how the immune system responds to these two viruses will help to reduce heterosexual spread of HIV.
Evaluation Of Immune Correlates For Virus-specific CD8+ T Cells Following Prime-boost Vaccination
Funder
National Health and Medical Research Council
Funding Amount
$397,889.00
Summary
This project will use cutting-edge technology to evaluate the quality of virus-specific white blood cells generated following vaccination. Clinically relevant vaccination strategies will be analysed in a well characterised mouse model of infection to produce correlates associated with protective vaccine efficacy, particularly in an immunosupressed setting. This will lead to more focused research and ultimately the development of prophylactic and therapeutic HIV vaccines.
Modulation Of HIV-1 Specific T Cell Function By Toll-like Receptor Ligands
Funder
National Health and Medical Research Council
Funding Amount
$214,584.00
Summary
Toll-like receptors (TLR) are highly conserved molecules which allow cells to recognize foreign materials. Factors that bind to these TLRs are called ligands. Ligands that activate or suppress TLR may play a crucial role in influencing how the immune system recognizes and controls HIV. A better understanding of the mechanisms by which TLR ligands, including components of HIV-1, modulate T cell function will open up new avenues for the design of immunotherapeutic interventions and vaccines.
Viral Reservoirs:Role Of Naive T-cells In The Pathogeneisis Of T-cell Decline And Longterm Persistence Of HIV Infection.
Funder
National Health and Medical Research Council
Funding Amount
$85,716.00
Summary
Despite dramatic advances in treatment for HIV infection, HIV cannot be cured. The main reason why cure is not possible is because HIV can persist in long lived cells and these infected cells are not recognised by the immune system. This project will examine the role of a particular type of infection fighting cell, the naive T-cell, in long term persistence of HIV. The project will determine how naive T-cells are infected with HIV and what happens to these cells following HIV treatment.